CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Significance: Epigenetic inhibitors have shown considerable promise for the treatment of malignant and inflammatory diseases. We present here the detailed characterization of a potent and highly selective inhibitor of the bromodomains of CBP (CREB binding protein)/p300. Functional preclinical data studying cells derived from patients with ankylosing spondylitis and psoriatic arthritis (two human Th17-driven diseases) show that selective inhibition of the CBP/p300 bromodomain with CBP30 strongly reduces secretion of IL-17A, without having the broader and potentially deleterious effects on cytokine production and gene transcription of the pan-BET (bromo and extraterminal domain protein family) inhibitor JQ1. CBP/p300 play a significant role in IL-17A production, and CBP/p300 inhibition is a promising therapeutic strategy in human type-17–mediated diseases such as ankylosing spondylitis and psoriatic arthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
PRODRG: a tool for high-throughput crystallography of protein–ligand complexes
Schüttelkopf, A. W., & van Aalten, D. M. F. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904011679 · Cited by 4,804
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 2×
“cDNA encoding human bromodomains was cloned, expressed, and purified as previously described (10).”
BackgroundMethodSelf-citationPhenotypic and functional features of human Th17 cells
Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B., Parente, E., Filì, L., Ferri, S., Frosali, F., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070663 · Cited by 1,861
Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7
Langer, G., Cohen, S. X., Lamzin, V. S., & Perrakis, A. (2008) · Nature Protocols · doi:10.1038/nprot.2008.91 · Cited by 1,606
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585 · cited 1×
“CBP/p300 is thought to be involved at an early stage, consistent with our data showing key sensitivity of human IL 17A transcription to CBP/p300 inhibition (38, 39).”
BackgroundSuppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563 · cited 1×
“BET bromodomain inhibitors exhibit antiinflammatory activity by inhibiting expression of inflammatory genes (11).”
BackgroundInhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
An introduction to data reduction: space-group determination, scaling and intensity statistics
Evans, P. R. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s090744491003982x · Cited by 1,485
Targeting bromodomains: epigenetic readers of lysine acetylation
Filippakopoulos, P., & Knapp, S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4286 · Cited by 1,243
Self-citationA Validated Regulatory Network for Th17 Cell Specification
Ciofani, M., Madar, A., Galan, C., Sellars, M., Mace, K., Pauli, F., Agarwal, A., Huang, W., Parkurst, C. N., Muratet, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.09.016 · Cited by 1,160
Wei, G., Wei, L., Zhu, J., Zang, C., Hu-Li, J., Yao, Z., Cui, K., Kanno, Y., Roh, T.-Y., Watford, W. T., et al. (2009) · Immunity · doi:10.1016/j.immuni.2008.12.009 · Cited by 1,152
The Australo-Anglo-American Spondyloarthritis Consortium (TASC), Evans, D. M., the Wellcome Trust Case Control Consortium 2 (WTCCC2), Spondyloarthritis Research Consortium of Canada (SPARCC), Spencer, C. C. A., Pointon, J. J., Su, Z., Harvey, D., Kochan, G., Oppermann, U., et al. (2011) · Nature Genetics · doi:10.1038/ng.873 · Cited by 893
Self-citationA small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription
Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M., Moon, R. T., Teo, J.-L., Oh, S. W., Kim, H. Y., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404875101 · Cited by 874
CREB-binding Protein and p300 in Transcriptional Regulation
Vo, N., & Goodman, R. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r000025200 · Cited by 866
International Genetics of Ankylosing Spondylitis Consortium (IGAS) (2013) · Nature Genetics · doi:10.1038/ng.2667 · Cited by 860
McInnes, I. B., Kavanaugh, A., Gottlieb, A. B., Puig, L., Rahman, P., Ritchlin, C., Brodmerkel, C., Li, S., Wang, Y., Mendelsohn, A. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60594-2 · Cited by 807
Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis
Matusevicius, D., Kivisäkk, P., He, B., Kostulas, N., Özenci, V, Fredrikson, S., & Link, H. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500206 · Cited by 751
Global prevalence of ankylosing spondylitis
Dean, L. E., Jones, G. T., MacDonald, A. G., Downham, C., Sturrock, R. D., & Macfarlane, G. J. (2014) · Rheumatology · doi:10.1093/rheumatology/ket387 · Cited by 722
Baeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., McInnes, I., van Laar, J. M., Landewé, R., Wordsworth, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61134-4 · Cited by 595
Self-citationChronically Inflamed Human Tissues Are Infiltrated by Highly Differentiated Th17 Lymphocytes
Pène, J., Chevalier, S., Preisser, L., Vénéreau, E., Guilleux, M.-H., Ghannam, S., Molès, J.-P., Danger, Y., Ravon, E., Lesaux, S., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7423 · Cited by 527
Shen, H., Goodall, J. C., & Hill Gaston, J. S. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24568 · Cited by 516
Bromodomains as therapeutic targets
Muller, S., Filippakopoulos, P., & Knapp, S. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001992 · Cited by 442
Self-citationBelkina, A. C., Nikolajczyk, B. S., & Denis, G. V. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202838 · Cited by 418
Small-Molecule Inhibition of BRDT for Male Contraception
Matzuk, M. M., McKeown, M. R., Filippakopoulos, P., Li, Q., Ma, L., Agno, J. E., Lemieux, M. E., Picaud, S., Yu, R. N., Qi, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.045 · Cited by 416
Self-citationJandus, C., Bioley, G., Rivals, J., Dudler, J., Speiser, D., & Romero, P. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23655 · Cited by 382
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Ciceri, P., Müller, S., O'Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1471 · Cited by 338
Self-citationBowness, P., Ridley, A., Shaw, J., Chan, A. T., Wong-Baeza, I., Fleming, M., Cummings, F., McMichael, A., & Kollnberger, S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002653 · Cited by 304
Self-citationStructure of the p300 catalytic core and implications for chromatin targeting and HAT regulation
Delvecchio, M., Gaucher, J., Aguilar-Gurrieri, C., Ortega, E., & Panne, D. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2642 · Cited by 303
Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites
Vidler, L. R., Brown, N., Knapp, S., & Hoelder, S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300346w · Cited by 278
Self-citationDiscovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
Hay, D. A., Fedorov, O., Martin, S., Singleton, D. C., Tallant, C., Wells, C., Picaud, S., Philpott, M., Monteiro, O. P., Rogers, C. M., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja412434f · Cited by 277
Self-citationPFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains
Picaud, S., Da Costa, D., Thanasopoulou, A., Filippakopoulos, P., Fish, P. V., Philpott, M., Fedorov, O., Brennan, P., Bunnage, M. E., Owen, D. R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3292 · Cited by 249
Self-citationBET bromodomain inhibition suppresses TH17-mediated pathology
Mele, D. A., Salmeron, A., Ghosh, S., Huang, H.-R., Bryant, B. M., & Lora, J. M. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130376 · Cited by 229
3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands
Hewings, D. S., Wang, M., Philpott, M., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Vuppusetty, C., Marsden, B., Knapp, S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200640v · Cited by 216
Self-citationIdentification of small-molecule antagonists that inhibit an activator:coactivator interaction
Best, J. L., Amezcua, C. A., Mayr, B., Flechner, L., Murawsky, C. M., Emerson, B., Zor, T., Gardner, K. H., & Montminy, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406374101 · Cited by 207
The Epidemiology of Back Pain, Axial Spondyloarthritis and HLA-B27 in the United States
Reveille, J. D., & Weisman, M. H. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318294457f · Cited by 190
Roderick, J. E., Tesell, J., Shultz, L. D., Brehm, M. A., Greiner, D. L., Harris, M. H., Silverman, L. B., Sallan, S. E., Gutiérrez, A., Look, A. T., et al. (2014) · Blood · doi:10.1182/blood-2013-08-522698 · Cited by 176
Kinase Inhibitor Selectivity Profiling Using Differential Scanning Fluorimetry
Fedorov, O., Niesen, F. H., & Knapp, S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-337-0_7 · Cited by 158
Self-citationEfficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
Burmester, G. R., Weinblatt, M. E., McInnes, I. B., Porter, D., Barbarash, O., Vatutin, M., Szombati, I., Esfandiari, E., Sleeman, M. A., Kane, C. D., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202450 · Cited by 157
Transcription of Il17 and Il17f Is Controlled by Conserved Noncoding Sequence 2
Wang, X., Zhang, Y., Yang, X. O., Nurieva, R. I., Chang, S. H., Ojeda, S. S., Kang, H. S., Schluns, K. S., Gui, J., Jetten, A. M., et al. (2012) · Immunity · doi:10.1016/j.immuni.2011.10.019 · Cited by 127
Mechanism of p300 Specific Histone Acetyltransferase Inhibition by Small Molecules
Arif, M., Pradhan, S. K., G R, T., Vedamurthy, B. M., Agrawal, S., Dasgupta, D., & Kundu, T. K. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800657z · Cited by 118
Rooney, T. P. C., Filippakopoulos, P., Fedorov, O., Picaud, S., Cortopassi, W. A., Hay, D. A., Martin, S., Tumber, A., Rogers, C. M., Philpott, M., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201402750 · Cited by 115
Self-citationChemical target and pathway toxicity mechanisms defined in primary human cell systems
Berg, E. L., Yang, J. B., Melrose, J. E., Nguyen, D., Privat, S., Rosler, E. S., Kunkel, E. J., & Ekins, S. (2009) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2009.10.001 · Cited by 86
Philpott, M., Rogers, C. M., Yapp, C., Wells, C. D., Lambert, J., Strain-Damerell, C. M., Burgess-Brown, N., Gingras, A., Knapp, S., & Müller, S. (2014) · Epigenetics & Chromatin · doi:10.1186/1756-8935-7-14 · Cited by 82
Self-citationDynamic bookmarking of primary response genes by p300 and RNA polymerase II complexes
Byun, J. S., Wong, M., Cui, W., Idelman, G., Li, Q., Siervi, A. D., Bilke, S., Haggerty, C. M., Player, A. N., Wang, Y. H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905469106 · Cited by 67
Analysis of Gene Expression and Gene Silencing in Human Macrophages
Martínez, F. O. (2012) · Current Protocols in Immunology · doi:10.1002/0471142735.im1428s96 · Cited by 35
Cited by
Bromodomains: a new target class for drug development
Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 412
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 375
Bromodomain inhibitors and cancer therapy: From structures to applications
Pérez-Salvia, M., & Esteller, M. (2017) · Epigenetics · doi:10.1080/15592294.2016.1265710 · Cited by 292
Prostaglandin‐cytokine crosstalk in chronic inflammation
Yao, C., & Narumiya, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14530 · Cited by 283
Chen, Q., Yang, B., Liu, X., Zhang, X. D., Zhang, L., & Liu, T. (2022) · Theranostics · doi:10.7150/thno.73223 · Cited by 261
Metadata
- Authors
- Hammitzsch, A., Tallant, C., Fedorov, O., O’Mahony, A., Brennan, P. E., Hay, D. A., Martinez, F. O., Al-Mossawi, M. H., de Wit, J., Vecellio, M., Wells, C., Wordsworth, P., Müller, S., Knapp, S., & Bowness, P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2015-08-10
- Volume
- 112
- Issue
- 34
- Pages
- 10768-10773
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1945410182
- Cited by
- 254
- References
- 50
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.